RxDoctor Payments Data

Sarit Polsky

Endocrinology, Diabetes & Metabolism · Aurora, CONPI 1689862641

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (46.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 60.2% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2020 at $5,413 and has fallen 52.5% since, to $2,570 in 2025.

$9,726in general payments, 2019–2025

Across 44 payments — averaging $221.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$6K
  • Insulet Corporation$2K
  • Dexcom, Inc.$559
  • Tandem Diabetes Care, Inc.$550
  • Abbott$451
  • Corcept Therapeutics$144
  • plus $46 from 1 others
$584,465in research payments, 2019–2025

Across 23 payments — averaging $25,412 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Dexcom, Inc.$366K
  • Medtronic$219K

What the payments were for

  • Consulting fees$4,50046%
  • Speaking & faculty fees$8509%
  • Grants$571%
  • Travel & lodging$2,13022%
  • Food & beverage$2,18923%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,726 in reported general payments places this provider in the 80th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.

See all endocrinology, diabetes & metabolism providers in Colorado

Medicare billing

Part B allowed, 2024
$5,882
Medicare patients
17
Services billed
63

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide16$20,088
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/714$16,762
HumalogInsulin Lispro14$4,653
NovologInsulin Aspart12$3,767
Humalog Kwikpen U-100Insulin Lispro14$3,132
Rosuvastatin Calcium14$231
Levothyroxine Sodium23$195
Metformin Hcl19$110
Atorvastatin Calcium14$53
Losartan Potassium11$29

Paid to pharmacies, not to this prescriber.

Other endocrinology, diabetes & metabolism in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →